Review
Oct 2026
Precision toxicity control in checkpoint immunotherapy.
Immune checkpoint inhibitors have changed cancer management. However, immune-related adverse events (irAEs) can disrupt treatment and limit effective combination strategies. The standard of care tends to involve broad immunosuppression, which may compromise antitumor immunity and fail to address the dominant biology of...
Zhen Sun, Xiao-Yi Yang, Wei-Ming Shen et al.
· TIPS - Trends in Pharmacolog... · 0 citations